Creative Planning’s Akero Therapeutics AKRO Stock Holding History

Creative Planning’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-40,341	Closed	-$1.92M	–	3902
2025 Q3	$1.92M	Sell	40,341 -3,992	-9%	-$193K	﹤0.01%	1584
2025 Q2	$2.37M	Buy	44,333 +25,643	+137%	+$1.17M	﹤0.01%	1205
2025 Q1	$757K	Buy	18,690 +5,191	+38%	+$220K	﹤0.01%	1948
2024 Q4	$376K	Buy	13,499 +562	+4%	+$17K	﹤0.01%	2489
2024 Q3	$371K	Buy	+12,937	New	+$337K	﹤0.01%	2354

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Creative Planning's AKRO Position: Q4 2025 in Review

Creative Planning sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 40,341 shares — an estimated $1.92M sold.

Creative Planning first reported a position in AKRO in Q3 2024 and held it in 5 quarters. The position peaked at $2.37M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Creative Planning reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Creative Planning sold 40,341 Akero Therapeutics shares in Q4 2025, an estimated $1.92M.
Creative Planning first reported a position in Akero Therapeutics in Q3 2024 and held it in 5 quarters.
Creative Planning's Akero Therapeutics position peaked at $2.37M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Creative Planning's 13F filing for Q4 2025, filed 17 Feb 2026.